Kontakt   Links   Impressum   Datenschutzerklärung

Willkommen

Die Klinik stellt sich vor

Aktuelles

Patientenwegweiser

Sprechstunden

Kontakt


Roboterassistierte Chirurgie

Chemotherapie

Klinische Studien

Ihr Studienteam

Prostatakarzinom

Urothelkarzinom

Nierenzellkarzinom

Links

Tumorboard

Tumorzentrum

Prostatakrebszentrum

Onkologisches Zentrum
für Peniskarzinome

Familiäres PCA

Experimentelle Urologie

Dissertationen

Lehre

Publikationen

Symposien & Workshops

Newsletter

Das MRIU in der Presse

Links


Bleiben Sie in Kontakt

Urothelkarzinom

Nicht-muskelinvasives Blasenkarzinom

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Ausführliche Informationen

Nicht-muskelinvasives Blasenkarzinom

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemo-therapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (THOR2)

Ausführliche Informationen

Muskelinvasives Blasenkarzinom

A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post-Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC

Ausführliche Informationen

 

Muskelinvasives Blasenkarzinom

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)

Ausführliche Informationen

Metastasiertes Urothelkarzinom

A Study of Enfortumab-Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial cancer (EV-302)

Ausführliche Informationen

Metastasiertes Urothelkarzinom mUC nach Chemotherapie XL-092

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Ausführliche Informationen

Metastasiertes Urothelkarzinom mUC nach Chemotherapie
XL-092 und Immuntherapie

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Ausführliche Informationen

Metastasiertes Urothelkarzinom mUC nach Immuntherapie
Monotherapie mit XL-092

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Ausführliche Informationen